EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 255 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Breast Cancer Survivor Shares Inspiring Images Of Herself As “Bold Indian... March 1, 2019 Scanxiety September 15, 2021 Is there a future without Pap testing? October 21, 2020 Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α April 1, 2021 Load more HOT NEWS New Areolar Incision Technique Leaves Almost No Scars for Breast Cancer... Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... Bringing a Piece of Home to the Hospital EMA Recommends Extending Indications for Lisocabtagene Maraleucel
